Molecular Mass: 473.584 g/mol
Protein Binding: 95%
Half-Life: 27.7 Hours
Manufacturer: Eli Lilly & Company, Indianapolis, IN
Active Ingredient: Raloxifene hydrochloride
Inactive Ingredients: Anhydrous lactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide
is Eli Lilly & Companys brand name for raloxifen hydrochloride, a second-generation Selective Estrogen
Receptor Modulator (SERM) in the benzothiophene family. On September 13, 2007, the U. S. Food and Drug Administration approved Evista for reduction in the risk of invasive breast cancer in postmenopausal women with and without osteoporosis
. It has also been approved as a potent stand-alone osteoporosis treatment.
Essentially Evista is a non-steroidal, anti-estrogenic drug that possesses both estrogen agonist and antagonist properties. This means that how it acts estrogen promoting with regard to bones, or anti-estrogenic towards uterine and breast tissue depends on the absorption site, i.e. which receptors within the body are absorbing it.
Evista, and raloxifene hydrochloride in general, is most often found in the form of 60 mg tablets. One tablet should be taken daily with or without food. If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next dose, skip the missed dosage and take only the next regularly scheduled dose. Do not take two doses at the same time.
For bodybuilding/athletic purposes, within the male body, Evista primarily acts as an anti-estrogen. Aromatization is the process by which excess testosterone
is readily converted to excess estrogen, which when absorbed by various estrogen receptors throughout the body can incite numerous negative side effects the most hazardous of which is probably gynecomastia
) the development of female breast tissue in men, a condition caused by an imbalance in the testosterone to estrogen ratio.
actions are very similar to those of more popular anti-estrogens
frequently used within the anabolic steroid
community such as Tamoxifen (Nolvadex
) and Clomiphene Citrate
), two drugs that effectively block estrogens absorption because they are preferred by the estrogen receptors. Anabolic steroid
using bodybuilders and athletes take these drugs to prevent said estrogen absorption, causing it to instead continue circulating ineffectively throughout the bloodstream. Estrogens lack of absorption significantly reduces estrogenic side effects, as well as prohibits gynos
development by starving existing gyno growth of the nourishing estrogen necessary to sustain and/or increase it. Without access to estrogen gyno shrinks, and in most cases completely dissolves resulting in full resolution. In a small percentage of cases the growth persists, but shrinks substantially and remains susceptible to redevelopment in subsequent steroid cycles if not properly protected against.
There are a host of Eli Lilly and Company cited major possible side effects (of course for women only as per this drugs prescription population), but most are manufacturer safeguards like blood clots, stroke and death from either complication. For the male steroid user, Evista possesses potential for the same major side effects but of course the relatively minor ones are far more common such as irritability, mood swings, joint stiffness or pain, temporarily negative lipid panel & hepatic results, and possible libido hindrance.
Although Evista is the most prevalent brand of this drug, raloxifene hydrochloride is available in over 50 countries. The most likely reason for Evistas lack of popularity within the anabolic steroid community is cost. One Evista tablet/dose is typically more than $2, compared to the approximately fifty cents cost of a single 20 mg tablet/dose of Nolvadex.
Evista is typically administered after anabolic steroid cycles
, testosterone (propionate
, and cypionate
, Oral Turinabol
, and Halotestin
. This is called Post-Cycle Therapy (PCT), a process that bridges the time between cycle discontinuation and the restoration of HPTA.